epigallocatechin 3 o gallate/neoplasms

FIELD OF THE INVENTION The present invention relates to a nutrient pharmaceutical formulation and its use for the treatment of cancer. More specifically, the present invention relates to polyphenol containing pharmaceutical formulations having an effective amount of polyphenols for the treatment of

1. INTRODUCTION The present invention relates to novel methods and compositions for the treatment of primary and metastatic cancers. These methods and compositions utilize catechins, including but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), and

1. INTRODUCTION The present invention relates to novel methods and compositions for the treatment of primary and metastatic cancers. These methods and compositions utilize catechins, including but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), and

1. INTRODUCTION The present invention relates to novel methods and sustained release compositions which utilize catechins, including but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin (EGC), which are found in varying levels in tea

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable REFERENCE TO SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISK APPENDIX Not Applicable BACKGROUND OF THE INVENTION The present invention relates to novel methods and compositions which utilize

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of pharmacology and tumor biology. More specifically, the present invention relates to secretion of nucleoside diphosphate kinase (NDPK) from human tumors and the effects of inhibiting

1. INTRODUCTION The present invention relates to novel methods and compositions which utilize catechins, including but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin (EGC), which are found in varying levels in tea leaves, in

FIELD OF THE INVENTION This invention relates to derivates of (-)-epigallocatechin gallate, particularly for use as proteasome inhibitors and/or for inhibition of cancer cell growth. BACKGROUND OF THE INVENTION The polyphenols found in green tea extracts are (-)-epicatechin (EC),

FIELD OF THE INVENTION This invention relates to derivates of (-)-epigallocatechin gallate, particularly for use as proteasome inhibitors and/or for inhibition of cancer cell growth. BACKGROUND OF THE INVENTION The polyphenols found in green tea extracts are (-)-epicatechin (EC),

FIELD OF THE INVENTION The invention relates to cosmetic and pharmaceutical treatment methods. More specifically, the invention relates to treatment of angiogenesis-related disorders, particularly skin disorders. BACKGROUND OF THE INVENTION Angiogenesis, which is the process of producing new

FIELD OF THE INVENTION The field of the invention is pharmaceutical agents for treatment and chemoprevention of neoplastic diseases. BACKGROUND OF THE INVENTION Green tea extracts and their isolated constituents have been described in numerous reports as antineoplastic agents. For example, U.S. Pat.

FIELD OF THE INVENTION This invention relates to treatment for the inhibition of lung tumorigenesis by the administration of a pharmaceutical compound and to the pharmaceutical compound which is administered. BACKGROUND It has been noted that the lung cancer mortality among males in Japan is

1. INTRODUCTION The present invention relates to novel compositions of catechins, including but not limited to, epigallocatechin gallate (EGCg), the major catechin in green tea leaves, epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin (EGC), which are found in varying levels in tea